[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.171.35. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 645
Citations 0
News From the Food and Drug Administration
August 18, 2015

Heart Failure Drug Gains Approval

JAMA. 2015;314(7):662. doi:10.1001/jama.2015.9770

The FDA has approved sacubitril/valsartan, marketed as Entresto, to treat patients with heart failure. The drug was granted fast-track designation as a medication that treats a serious or life-threatening condition and fills an unmet medical need.

In a trial including more than 8000 adults, Entresto was shown to reduce the rate of cardiovascular death and hospitalizations associated with heart failure compared with another drug, enalapril (http://1.usa.gov/1Uxv4Dv). Most patients in the study also took other approved heart failure medications, including β-blockers, diuretics, and mineralocorticoid antagonists.

First Page Preview View Large
First page PDF preview
First page PDF preview
×